Cikarang, June 25, 2024 – In alignment with the government’s commitment to enhancing Indonesia's healthcare system resilience and independence, PT Prodia Diagnostic Line proudly announces the expansion of its production facilities with a topping-off ceremony. This move will accommodate increasing market demand and support the goverment program.

As a pioneer in Indonesia's in vitro diagnostic medical device industry with over 14 years of experience, PT Prodia Diagnostic Line is enhancing its production capacity with a new plant located in the Jababeka III Industrial Area, Cikarang. Spanning more than 10,000 square meters, this facility is designed to substantially increase our production of chemical chemistry reagents and hematology reagents, hematology reagents, anaylzers/instruments, molecular reagents, etc.

The topping off of new facility production was attended by notable figures, including: 

• Drs. Andi Wijaya Ph.D – Commissioner and Founder of PT Prodia Widyahusada Tbk.
• Dra. Endang Hoyaranda – Director of PT Prodia Utama (Shareholder of PT Prodia Diagnostic Line)
• Dr. Günther Gorka – CEO of DiaSys Diagnostics System GmbH (Shareholder of PT Prodia Diagnostic Line)
• Dr. Cristina Sandjaja, M.Kes MM – Director of PT Prodia Diagnostic Line

This expansion underscores PT Prodia Diagnostic Line’s dedication to supporting the government's national health resilience system reform initiative. Our new facility ensures the consistent availability of high-quality in vitro diagnostic medical devices produced domestically, reducing reliance on imported products and enhancing local healthcare provision.

The addition of this facility aligns with our strategic goal to address the growing market demand for in vitro diagnostic (IVD) products that meet global quality standards. In the new plant, we will broaden our product portfolio to include advanced laboratory instruments, CLIA (chemiluminescence immunoassay) reagents, and molecular reagents, developed using cutting-edge technology.

Our original plant, operational since October 15, 2011, has supplied various routine chemical reagents to thousands of healthcare facilities nationwide. In 2023, we expanded our product line of hematology reagents compatible with a wide range of hematology instruments used across Indonesia. These Proline products, featured in the e-catalog with a Local Component Level (TKDN) of >40%, reflect our commitment to quality and local content.

The second facility not only amplifies our production capacity but also allows us to produce a diverse array of OEM (Original Equipment Manufacturer) products for our partners, adhering to the highest quality standards. With this new production facility, we are confident in our ability to meet the increasing domestic demand for high-quality medical devices and contribute significantly to national health resilience in the face of global health challenges.